Haasdonk, Belgium

Tom Vanden Berghe


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018-2022

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tom Vanden Berghe: Innovator in Pharmaceutical Chemistry

Introduction

Tom Vanden Berghe is a notable inventor based in Haasdonk, Belgium. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit cell death. With a total of 2 patents, his work focuses on innovative solutions for treating various medical conditions.

Latest Patents

Vanden Berghe's latest patents include the invention of 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues. These compounds serve as cell death inhibitors for conditions such as stroke, myocardial infarction, and neurodegenerative diseases. His second patent involves 3,4-diaminobenzenesulfonamide derivatives, which also aim to inhibit cell death and provide therapeutic benefits.

Career Highlights

Throughout his career, Vanden Berghe has worked with esteemed institutions such as Universiteit Antwerpen and VIB. His research has led to advancements in pharmaceutical compositions and methods for treating various health conditions. His innovative approach has garnered attention in the scientific community.

Collaborations

Tom Vanden Berghe has collaborated with notable colleagues, including Peter Vandenabeele and Koen Augustyns. These partnerships have contributed to the success of his research and the development of his patented inventions.

Conclusion

Tom Vanden Berghe is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of serious medical conditions. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…